Sunitinib News and Research

RSS
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Chi-Med announces initiation of Phase III sulfatinib registration trial in patients with NETs in China

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison MediPharma begins sulfatinib Phase I trial in US

New clinical trial uses aggressive treatment method for patients with pancreas cancer

New clinical trial uses aggressive treatment method for patients with pancreas cancer

Poorly-designed animal study threatens validity of preclinical research

Poorly-designed animal study threatens validity of preclinical research

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer benefit from cabozantinib treatment

Tolerability benefits with sunitinib schedule switch

Tolerability benefits with sunitinib schedule switch

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

SNPs predict sunitinib outcome in mRCC

SNPs predict sunitinib outcome in mRCC

‘Real-world’ sunitinib findings support trial results

‘Real-world’ sunitinib findings support trial results

RCC benefit independent of sorafenib, sunitinib sequence order

RCC benefit independent of sorafenib, sunitinib sequence order

Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

Study compares effectiveness of treatments for metastatic non-clear cell kidney cancers

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Alternating sunitinib, everolimus not supported in advanced RCC

Alternating sunitinib, everolimus not supported in advanced RCC

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

Study reveals conclusive results in reducing toxicities for Asian patients with mRCC

Study reveals conclusive results in reducing toxicities for Asian patients with mRCC

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Sunitinib holds promise for treatment of advanced differentiated thyroid cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer